uniQure and Chiesi announce six year follow-up data from Glybera uniQure and Chiesi Farmaceutici announced initial analysis of retrospectively collected individual patient data from LPLD patients treated with Glybera. The analysis covers follow-up data for up to six years post treatment for 13 patients, all of whom met indication requirements for the current labeling of Glybera in the EU. The review suggests that treatment with Glybera provides long-term beneficial effects with regard to the risk of encountering new pancreatitis events, including the occurrence of severe pancreatitis events. These results are in line with the trend exhibited in the first case note review performed up to 3 years after treatment with Glybera.
News For QURE From The Last 14 Days
Check below for free stories on QURE the last two weeks.